An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

• Walter Fiedler,
• Pau Montesinos,
• Christoph Schliemann,
• Jan Middeke,
• Sumithira Vasu,
• Christian W. Scholz,
• Jordi Esteve,
• Shoubhik Mondal,
• Björn Rüter,
• Ute Burkard,
• Annika Osswald,
• William Blum

Affiliations

Walter Fiedler

Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg

Pau Montesinos

Hospital Universitari i Politecnic La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid

Christoph Schliemann

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster

Jan Middeke

Uniklinikum Dresden, Dresden

Sumithira Vasu

Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Christian W. Scholz

Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin

Jordi Esteve

Hematology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona

Shoubhik Mondal

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Björn Rüter

BoehringeaBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Rissr Ingelheim Pharma GmbH and Co. KG, Biberach/Riss

Ute Burkard

Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss

Annika Osswald

Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss

William Blum

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA